The enhanced anti-tumoral effect of CD8+ T cells as consequence of pharmacological inhibition of CSF-1/CSF-1R axis has also been exploited for combinational therapy with ICBs, especially for tumours resistant to single-agent therapy. Here, CD8A is linked to neoplasm.